<DOC>
	<DOCNO>NCT00144963</DOCNO>
	<brief_summary>The purpose study find high safe dose assess anti-tumor effect liposomal vincristine dexamethasone patient relapse refractory acute lymphoblastic leukemia ( ALL ) .</brief_summary>
	<brief_title>Liposomal Vincristine Plus Dexamethasone Patients With Relapsed Refractory Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ( MTD ) liposomal vincristine give dexamethasone patient relapsed refractory acute lymphoblastic leukemia ( ALL ) . - Determine efficacy liposomal vincristine give dexamethasone patient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Previously treat , relapse refractory ALL ( include lymphoblastic lymphoma Burkitt 's subtypes ) measurable disease . Performance status ≤3 ( ECOG ) . All age eligible . Those age 12 year old may count towards MTD Phase I portion trial . Pediatric patient eligible , must treat dose level previously test adult ( one full course ) . Adequate liver function ( bilirubin ≤2 x upper limit normal ) , renal function ( creatinine ≤2 x upper limit normal ) . Negative pregnancy test female childbearing potential . Patients prior history stem cell transplant eligible meet eligibility requirement . Active serious infection control oral intravenous antibiotic . Treatment investigational agent chemotherapy agent last 21 day study entry , unless full recovery side effect occur patient rapidly progressive disease judge life threaten Investigator . Concurrent treatment anticancer agent dexamethasone . Known CNS leukemia lymphoma require intrathecal craniospinal radiation therapy CNS neuropathy limit evaluation study drug . Patients control CNS disease ( progression sign symptom time study entry ) may eligible approval Principal Investigator . Lumbar puncture require asymptomatic patient . Prior history Grade 3 4 sensory motor neuropathy relate chemotherapeutic treatment , persistent Grade 2 great active neuropathy . History active neurologic disorder unrelated chemotherapy ( include familial neurologic disease acquire demyelinate disorder ) . Prior history hypersensitivity reaction vincristine component VSLI . Pregnant and/or lactate woman ; fertile men woman willing use contraception .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>